Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.5%) at 16,894 as of Thursday, July 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 864 issues advancing vs. 2,123 declining with 163 unchanged. The Drugs industry currently sits down 1.0% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Sanofi ( SNY), down 1.2%, Valeant Pharmaceuticals International ( VRX), down 1.0%, Novartis ( NVS), down 0.8%, Allergan ( AGN), down 0.6% and Amgen ( AMGN), down 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.64 (-0.8%) to $74.40 on light volume. Thus far, 585,730 shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $74.08-$74.66 after having opened the day at $74.13 as compared to the previous trading day's close of $75.04. AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $94.3 billion and is part of the health care sector. Shares are up 26.4% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold. TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.